Dimerix Limited
ASX: DXB.AX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Nina Webster
- Headquarters
- Fitzroy, Australia
- IPO year
- 1989
- Market cap
- A$129.1M
- Website
- https://dimerix.com
Loading DXB…
Loading profile data…Frequently asked questions about DXB
What does Dimerix Limited (DXB.AX) do?
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200 that is in two Phase 3 clinical trials for COVID respiratory complications; DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-7...
Where does DXB.AX trade?
Dimerix Limited (DXB.AX) trades on the Australian Securities Exchange.
What sector is DXB.AX in?
Dimerix Limited (DXB.AX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Dimerix Limited?
Nina Webster is the chief executive officer of Dimerix Limited (DXB.AX).
Where is Dimerix Limited headquartered?
Dimerix Limited is headquartered in Australia.
Does DXB.AX pay a dividend?
Dimerix Limited (DXB.AX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DXB.AX go public?
Dimerix Limited (DXB.AX) completed its initial public offering in 1989.